Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

Starting soon · Phase 1/Phase 2

Conditions studied: Metastatic Pancreatic Ductal Adenocarcinoma

In brief

The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.

Key facts

Study ID

NCT07640295

Run by

Jacobio Pharmaceuticals Co., Ltd.

People needed

80

Starts

2026-06-22

Expected to finish

2030-12-31

Last updated by the study team

2026-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent signed by the participant or the participant's legally authorized representative must be obtained prior to performing any study-related procedures. 2. Histologically or cytologically confirmed metastatic PDAC.
• No prior systemic antitumor therapy for advanced disease (treatment-naïve). 4. Presence of KRAS gene alterations: be enrolled upon approval by the sponsor).
• ECOG performance status score of 0 or 1. 6. Adequate organ function.

You may not qualify if…

• Inability to swallow oral medications or the presence of gastrointestinal dysfunction or disease that may significantly alter drug absorption.
• A history of another malignancy within 2 years prior to the first dose, histologically distinct from the cancer under study, except for carcinoma in situ of the cervix, superficial non-invasive bladder cancer, or adequately treated stage I non-melanoma skin cancer.
• Prior treatment with KRAS G12C inhibitors, KRAS G12D inhibitors, pan-KRAS inhibitors, or other agents of the same class.
• Primary central nervous system (CNS) tumors.
• Women who are pregnant or breast-feeding.
• Participants who have progressive disease or recurrence during neoadjuvant or adjuvant treatment, or within 6 months after the last dose of medication.

Where it is running

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China
• Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China
• Beijing Tsinghua Changgung Hospital — Beijing, China
• Hunan Cancer Hospital — Changsha, China
• Harbin Medical University Cancer Hospital — Harbin, China
• Jiangsu Province Hospital — Nanjing, China
• Shanghai Jiaotong University School of Medicine Ruijin Hospital — Shanghai, China
• ShanXi Cancer Hospital — Taiyuan, China
• Hubei Province Hospital — Wuhan, China
• Wuhan Union Hospital Of China — Wuhan, China
• Zhongnan Hospital of Wuhan University — Wuhan, China
• Henan Cancer Hospital — Zhengzhou, China
• The First Affiliated hospital of Zhengzhou University — Zhengzhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.